We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn about our cookie policy.
Sigma-Aldrich Plga Microspheres 25Um Average Diameter
List Price
$664.00
Your Price
$664.00
Sigma-Aldrich Plga Microspheres 25Um Average Diameter - SIALGSK (Additional S&H or Hazmat Fees May Apply)
NETA PART:
SIALGSK-942219-50MG
MFG.PART:
942219-50MG
UNSPSC:
41116113
Manufacturer:
Sigma-Aldrich
form
pellets
Quality Level
100
mol wt
MW 30000 Da
average diameter
25 μm
density
1.3 g/cm3
storage temp.
−20°C
General description
PLGA (poly(lactic-co-glycolic acid)) is a biodegradable and biocompatible polymer, FDA-approved for biomedical applications. Upon administration, the PLGA polymer degrades through hydrolysis of its ester backbone into non-toxic byproducts. For drug-loaded particles, the drug molecules are gradually released, and this release rate can be fine-tuned by selecting different types of PLGA and adjusting the encapsulation process.
Factors that influence the degradation and drug release rates include:
Factors that influence the degradation and drug release rates include:
- Lactide to glycolide (L/g) ratio: a 50:50 L/g ratio exhibits the fastest drug release
- Molecular weight: Higher molecular weights result in slower release
- Terminal groups: Carboxyl-terminated PLGA polymer provide quicker release compared to ester-terminated PLGA
Application
Degradex® PLGA microspheres are ideal for a wide range of biomedical and pharmaceutical R&D applications, including:
- Controlled drug release: The gradual degradation of PLGA allows for sustained release of encapsulated drug molecules, improving therapeutic efficacy and reducing dosing frequency.
- Bioavailability enhancement: PLGA microspheres can improve the solubility and stability of poorly water-soluble drugs, enhancing their bioavailability.
- Drug targeting: The microsphere structure enables targeted drug delivery to specific tissues or cells, potentially reducing side effects and improving treatment outcomes.
- API stabilization: Encapsulation in PLGA microspheres can protect sensitive active pharmaceutical ingredients (APIs) from degradation.
- System compatibility testing: These plain PLGA microspheres serve as excellent models for testing system compatibility before incorporating your specific API.
- Drug attachment and delivery: The microspheres can act as carriers, allowing drug molecules to be attached to their surface for efficient delivery.
Features and Benefits
Degradex PLGA microspheres are made with poly(D,L-lactide-co-glycolide) with an L/g ratio of 50/50 and a MW of 30,000.
Key Features:
Average diameter: 25µm +/- 3µm
Standard deviation: <25%
Fluorescence: None
Degradex microspheres are designed to be reconstituted in an aqueous medium, such as deionized water or buffer, for common applications. It is crucial to ensure the particles are well suspended as a single-particle suspension without aggregation before use.
Reconstitution Instructions:
Key Features:
Average diameter: 25µm +/- 3µm
Standard deviation: <25%
Fluorescence: None
Degradex microspheres are designed to be reconstituted in an aqueous medium, such as deionized water or buffer, for common applications. It is crucial to ensure the particles are well suspended as a single-particle suspension without aggregation before use.
Reconstitution Instructions:
- Remove the product from the freezer.
- Allow it to REACH ambient temperature.
- Add deionized water or buffer to the container.
- Gently mix the contents to ensure the particles are well suspended; vortexing or sonication may be necessary.
Legal Information
Product of Phosphorex, Inc.
Degradex is a registered trademark of Phosphorex, Inc.
| SKU | SIALGSK-942219-50MG |
|---|---|
| Supplier Part Number | 942219-50MG |
| UM | EA |
| UNSPSC | 41116113 |
| Manufacturer | Sigma-Aldrich |
| ProductLine | SIALGSK |
| Qty | 1 |
| MinOrderQty | 1 |
| Weight | 7.000000 |
| Lead Time | 9 |
| Energy Star | No |
| Green | No |
| Controlled | N |